AnaptysBio, Inc. (NASDAQ:ANAB) Receives $80.00 Average Target Price from Analysts

AnaptysBio, Inc. (NASDAQ:ANAB) has been assigned a consensus rating of “Moderate Buy” from the fifteen analysts that are covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, three have issued a hold rating and eleven have given a buy rating to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $79.8462.

ANAB has been the topic of a number of research analyst reports. Wolfe Research reaffirmed an “outperform” rating and issued a $78.00 target price on shares of AnaptysBio in a report on Monday. Wall Street Zen cut AnaptysBio from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 16th. TD Cowen lowered their price target on AnaptysBio from $75.00 to $70.00 and set a “buy” rating on the stock in a research report on Tuesday, August 25th. Zacks Research lowered AnaptysBio from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, June 2nd. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of AnaptysBio in a research report on Friday, August 7th.

AnaptysBio Price Performance

Shares of ANAB stock opened at $55.84 on Friday. The stock has a market cap of $1.65 billion, a P/E ratio of -51.70 and a beta of 0.71. The company has a fifty day moving average price of $58.35 and a two-hundred day moving average price of $59.17. AnaptysBio has a one year low of $11.40 and a one year high of $72.36.

Institutional Investors Weigh In On AnaptysBio

Several hedge funds have recently added to or reduced their stakes in ANAB. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in shares of AnaptysBio in the second quarter valued at $1,164,000. California State Teachers Retirement System boosted its holdings in shares of AnaptysBio by 8,399.7% during the 2nd quarter. California State Teachers Retirement System now owns 1,189,958 shares of the biotechnology company’s stock worth $80,322,000 after buying an additional 1,175,958 shares during the period. Irenic Capital Management LP bought a new stake in shares of AnaptysBio during the 2nd quarter worth about $4,755,000. Ancora Advisors LLC bought a new stake in shares of AnaptysBio during the 2nd quarter worth about $338,000. Finally, Hsbc Holdings PLC grew its stake in AnaptysBio by 72.6% in the 2nd quarter. Hsbc Holdings PLC now owns 216,949 shares of the biotechnology company’s stock valued at $14,928,000 after buying an additional 91,232 shares during the last quarter.

AnaptysBio Company Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.